Latest Research, Industry, Medical and Scientific News
Atlantic Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNOVO®, a non-invasive, clinically proven and wearable device that treats the root cause of bladder weakness, known clinically as stress urinary incontinence (SUI). INNOVO® was previously available in the U.S. by prescription, with more than 3.5 million safe and successful therapy sessions delivered worldwide. Read more.
Source: Yahoo! Finance, February 6, 2020
Contura has earned FDA approval for an injectable hydrogel [Bulkamid] to treat stress urinary incontinence in women, according to a premarket approval order posted by the agency Monday. The permanently implanted device acts as a scaffold for cells to grow through, supporting the closing mechanism of the urethra for better control of urine. Approval of the Bulkamid implant was based on a study of 228 women that showed 75% of those who got the device reported dryness or improvement in their symptoms. Read more.
Source: MedTechDive, February 4, 2020
Medtronic won EU regulatory clearance to introduce its InterStim Micro neurostimulator and InterStim SureScan MRI leads. The devices are used to deliver sacral neuromodulation therapy to treat overactive bladder (OAB), fecal incontinence, and non-obstructive urinary retention. The InterStim Micro is a much tinier version of Medtronic’s InterStim II neuromodulator, as it is 80% smaller, but it is a rechargeable device with an expected longevity of about 15 years. This is made possible partially thanks to so-called Overdrive technology that lets the battery maintain almost its full capacity to recharge throughout its working life. Read more.
Source: Medgadget, January 13, 2020
Researchers at the University of Bath have developed a simple point-of-care test for urinary tract infections that uses a smartphone camera. The system can rapidly detect the presence of E. coli in urine samples and could guide doctors in their decision to prescribe antibiotics, ensuring appropriate patient care and avoiding the overuse of antimicrobial medication. It can sometimes be difficult for clinicians to know whether to prescribe antibiotics. Unnecessary use of antibiotics is resulting in antimicrobial resistance, which will pose significant challenges to healthcare in the coming years. However, if a patient has an infection, such as a urinary tract infection (UTI), then antibiotics are undoubtedly warranted, but it can sometimes be difficult for a clinician to know for sure if a patient’s symptoms are caused by an infection. Read more.
Source: Medgadget, January 9, 2020
Bioness, a Valencia, California firm, won European regulatory approval for its StimRouter neuromodulation system to treat fecal incontinence. Previously cleared in the EU as a tool for managing chronic pain and overactive bladder, the new indication significantly expands the stated capabilities of this novel neuromodulation system. For the management of fecal incontinence, the StimRouter system targets the tibial nerve near the ankle. This is achieved thanks to a tiny implant and an external pulse transmitter patch that’s stuck to the skin over where the electronic lead implant is positioned. The entire outpatient procedure takes about thirty minutes to complete and relies on local anesthesia. Read more.
Source: Medgadget, January 8, 2020
NorthShore Care Supply, the company behind NorthShore brand premium adult diapers, will be moving to a new 173,000 square foot facility in Green Oaks, IL, in March 2020. The new building more than doubles the current space and will include NorthShore’s headquarters, U.S. fulfillment center, contact center, research & development as well as quality control lab. “It’s going to be an exciting year for our company as we complete our relocation and bring online our new fulfillment center with heavy investments in automation & robotics,” says Adam Greenberg, founder and president. “We also have planned investments in new products, advertising campaigns and an educational campaign designed to help end the blame, shame & stigma that exists around incontinence.” Read more.
Source: Nonwovens Industry, January 6, 2020